GAITHERSBURG, Md., May 21, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on May 21, 2024 in Hong Kong. Each of the following resolutions was passed at the EGM:
The Company is attending to the necessary filings with the Registrar of Companies in Cayman Islands to reflect the change of company name and director appointments. In addition, the Company is working with the Nasdaq Stock Market LLC to change the trading symbols of its ordinary shares and warrants.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.73 |
Daily Change: | 0.13 21.87 |
Daily Volume: | 234,550 |
Market Cap: | US$139.290M |
April 19, 2024 April 18, 2024 April 09, 2024 March 05, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB